BeyondSpring (BYSI) vs Citius Pharmaceuticals (CTXR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Citius Pharmaceuticals (CTXR) has outperformed BeyondSpring (BYSI) over the past year, losing 55.4% versus a loss of 82.8%. Over five years, BYSI leads with a -97.7% price change compared with -98.8% for CTXR. Citius Pharmaceuticals is the larger company by market cap ($14.0 million vs $13.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BYSI | CTXR |
|---|---|---|
| Share price | $0.33 | $0.5085 |
| Market cap | $13.66M | $13.96M |
| 1-day change | -24.49% | +2.27% |
| YTD return | -79.75% | -34.56% |
| 1-year return | -82.77% | -55.39% |
| 5-year return | -97.70% | -98.79% |
| EPS (TTM) | $-0.20 | $-1.75 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | — |
| Net income (latest FY) | $-1.01M | $-39.74M |
| 52-week high | $2.44 | $1.54 |
| 52-week low | $0.299 | $0.37 |
| Distance from 52-week high | -86.48% | -66.98% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +686.63% |
| Average volume | 261.79K | 275.44K |
| Shares outstanding | 41.41M | 27.45M |
| Employees | 44 | 23 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CTXR has outperformed BYSI by 27.4 percentage points over the past year.
About BeyondSpring
BYSI stock →BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on developing and selling clinical-stage biopharmaceutical therapies focused on oncology and immunology. The company operates through two segments: the Plinabulin pipeline and the TPD platform.
Health Care · Biotechnology: Pharmaceutical Preparations · 44 employees
About Citius Pharmaceuticals
CTXR stock →Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 23 employees
BYSI vs CTXR FAQ
Which is bigger, BeyondSpring or Citius Pharmaceuticals?
Citius Pharmaceuticals (CTXR) is larger, with a market capitalization of $13.96M compared with $13.66M for BeyondSpring (BYSI).
Which stock has performed better over the past year, BYSI or CTXR?
CTXR returned -55.39% over the past 12 months, compared with -82.77% for BYSI (price return, excluding dividends). Past performance does not predict future results.
Are BeyondSpring and Citius Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.